Novo Nordisk to Initiate P-IIIa Study for Oral Semaglutide to Treat Obesity

 Novo Nordisk to Initiate P-IIIa Study for Oral Semaglutide to Treat Obesity

Novo Nordisk to Initiate P-IIIa Study for Oral Semaglutide to Treat Obesity

Shots:

  • The company plan to initiate a pivotal P-IIIa program to assess the efficacy and safety of oral semaglutide (50mg) vs PBO in ~1000 people with obesity or overweight with comorbidities for 68wks.
  • The initiation follows the completion of the STEP P-IIIa clinical program with semaglutide (2.4mg, qw, SC). The study is expected to initiate the study in H2’21
  • Oral semaglutide is a convenient and effective treatment option for people with obesity and HCPs enabling broader use of anti-obesity medication

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Mehr News Agency

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post